Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyTue, 07 May 2024 23:48:48 +0200Wed, 27 Mar 2024 14:26:00 +0100Emgality : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-4648-en.pdfEmgality : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-4648-en.pdfWed, 27 Mar 2024 14:26:00 +0100Human medicineHuman medicines European public assessment report (EPAR): Emgality, galcanezumab, Date of authorisation: 14/11/2018, Revision: 11, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/emgalityHuman medicines European public assessment report (EPAR): Emgality, galcanezumab, Date of authorisation: 14/11/2018, Revision: 11, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/emgalityWed, 27 Mar 2024 11:48:00 +0100Human medicineOpinion/decision on a Paediatric investigation plan (PIP): Emgality, Galcanezumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0030/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001860-pip03-16-m08Opinion/decision on a Paediatric investigation plan (PIP): Emgality, Galcanezumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0030/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001860-pip03-16-m08Thu, 11 Jan 2024 11:40:00 +0100Human medicine